

Enesi Pharma, Sementis enter into R&D collaboration

05 November 2018 | News

The collaboration is focused on the development and evaluation of solid dose versions of Sementis' lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma's Implavax technology.



UK based Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, and Sementis, an Australian biotechnology company developing innovative vaccine candidates for the prevention of allergies and infectious diseases, have entered into a collaborative agreement.

The collaboration is focused on the development and evaluation of solid dose versions of Sementis' lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma's Implavax technology.

Implavax is an innovative and proprietary needle-free solid dose implant and device technology for subcutaneous vaccination. Data to date demonstrate that Implavax-enabled vaccines can deliver superior immune responses compared to standard injection protocols among other benefits such as safety, ease of use, reliability and stability.

Sementis' single vectored vaccine for chikungunya/Zika virus infection is promising with extensive proof-of-concept studies in mice demonstrating the effectiveness of the vaccine in protecting against Zika and chikungunya from a single vaccination shot.